Industry Symposium: OSTEOPOROSIS TREATMENTS: starting, sequencing and stopping – what is the long-term outlook?

Sponsored by

Clinical Professor Charles Inderjeeth, Australia
Dr Esther Briganti, Australia

Osteoporosis left untreated can have devastating consequences, yet some have called it an ‘orphan disease’ because there is debate as to which medical specialty should take the lead in advocacy and management. Endocrinologists, rheumatologists and primary care physicians are among those proposed. Irrespective of who should take the leadership role, osteoporosis is a key professional focus for rheumatologists: Many of the inflammatory conditions that they treat predispose patients to fragile bones, and the widespread use of corticosteroids further exacerbates this risk.

Recent results from long-term clinical trials of anti-osteoporosis therapies as well as findings from large database studies have led to an evolution of clinical treatment recommendations. This case-study based discussion between a leading Australian rheumatologist and prominent endocrinologist will provide updates on:

  • assessment of the safety and efficacy data for anti-osteoporosis treatments, including long-term risk/benefit profiles
  • switching between therapies and treatment cessation, reversibility differences and off-treatment effects
  • switching and sequential therapy options, including the role of anabolic agents.
Tuesday 9 April 2019
Time Topic Speaker
1030 – 1040 Welcome & Introduction Prof. Charles Inderjeeth
1040 – 1105 Case study 1: Female with osteoarthritis sustains a minimal trauma Colles’ fracture

  • First-line treatment options
  • Risk:benefit long-term treatment considerations
  • Discontinuing / transitioning treatment
Prof. Charles Inderjeeth
Dr Esther Briganti
1105 – 1130 Case study 2: Male with inflammatory arthritis sustains a fracture of the tibia

  • Osteoporosis in men
  • Secondary causes of osteoporosis
  • Second-line treatment
Prof. Charles Inderjeeth
Dr Esther Briganti
1130 – 1145 Panel discussion and Q&A Prof. Charles Inderjeeth
Dr Esther Briganti
1145 Symposium close Prof. Charles Inderjeeth

Attend this symposium for an informative discussion on first-line and second-line treatment options for osteoporosis. Gain clarity on starting, sequencing and stopping osteoporosis treatments for your patients at risk of fracture.